**HCQO 2020-21 Prescribing Indicator Definitions**

**People with diabetes with at least one prescription of cholesterol lowering medication**

**OECD indicator name**: Adequate use of cholesterol lowering treatment in people with diabetes.

**Coverage**: Population in the prescribing database with ≥1 prescription of ATC code A10B during the reference year.

**Numerator**: Number of people who are long-term users of glucose regulating medication (A10B) with concomitant use of ≥1 prescription of cholesterol lowering medication (C10).

**Denominator**: Number of people who are long-term users of glucose regulating medication (A10B) in the prescribing database. This is defined as individuals who use >270 defined daily doses of A10B per year.

**People with diabetes with prescription of first choice antihypertensive medication**

**OECD indicator name**: First choice anti-hypertensives for people with diabetes.

**Coverage**: Population in the prescribing database with ≥1 prescription of ATC code A10B during the reference year.

**Numerator**: Number of people who are long-term users of glucose regulating medication (A10B) with concomitant use of ≥1 prescription of angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) (C09, C10BX04, C10BX06, C10BX07, C10BX10, C10BX11, C10BX12, C10BX13, C10BX14, C10BX15).

**Denominator**: Number of people who are long-term users of glucose regulating medication (A10B) with concomitant use of ≥1 prescription of antihypertensives (ATC-C02) or diuretics (ATC C03) or beta-blockers (ATC C07) or calcium channel blockers (C08) or angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) (C09) or C10BX03 or C10BX04, or C10BX06, or C10BX07, or C10BX09, or C10BX10 or C10BX11or C10BX12 or C10BX13 or C10BX14 or C10BX15. Long-term users of A10B are defined as individuals who use >270 defined daily doses of A10B per year.

**Older patients with prescription of long-term benzodiazepines or related drugs**

**OECD indicator name**: Long-term use of benzodiazepines and benzodiazepine related drugs in people aged 65 years and over (>365 DDD in one year).

**Coverage**: Population aged 65 and over (at 1 January of the reference year) in the prescribing database with ≥1 prescription during the reference year.

**Numerator**: Number of individuals ≥65 years of age at 1 January in the prescribing database with >365 DDDs of benzodiazepines (N05BA or N05CD or N05CF or N03AE01) prescribed in the year.

**Denominator**: Number of individuals ≥65 years of age at 1 January in the prescribing database.

**Older patients with prescription of long-acting benzodiazepines or related drugs**

**OECD indicator name**: Use of long-acting benzodiazepines in people aged 65 years and over.

**Coverage**: Population aged 65 and over (at 1 January of the reference year) in the prescribing database with ≥1 prescription during the reference year.

**Numerator**: Number of individuals ≥65 years of age at 1 January in the prescribing database with ≥ 1 prescription of long-acting benzodiazepines (N05BA01, N05BA02, N05BA05, N05BA08, N05BA11, N05CD01, N05CD02, N05CD03, N05CD10).

**Denominator**: Number of individuals ≥65 years of age at 1 January in the prescribing database.

**Patients with long-term prescription of any anticoagulating drug in combination with an oral nonsteroidal anti-inflammatory drug (NSAID)**

**OECD indicator name**: Any anticoagulating drug in combination with an oral NSAID.

**Coverage**: Population in the prescribing database with ≥1 prescription during the reference year.

**Numerator**: Number of individuals who are long-term users of anticoagulating drugs acenocoumarol (B01AA07) or warfarin (B01AA03) or phenprocoumon (B01AA04) or dabigatran (B01AE07) or rivaroxaban (B01AF01) or apixaban (B01AF02) or Edoxaban (B01AF03) with concomitant use of ≥ 1 prescription of NSAID (M01A or M01B).

**Denominator**: Number of individuals who are long-term users of ATC-codes acenocoumarol (B01AA07) or warfarin (B01AA03) or phenprocoumon (B01AA04) or dabigatran (B01AE07) or rivaroxaban (B01AF01) or apixaban (B01AF02) or Edoxaban (B01AF03). This is defined as individuals who use >270 DDDs of the B01A codes listed above.

**Total volume of antibiotics for systemic use**

**OECD indicator name**: Overall volume of antibiotics for systemic use prescribed.

**Coverage**: Population in the prescribing database with ≥1 prescription during the reference year.

**Numerator**: Sum DDD of all ATC J01 prescriptions.

**Denominator**: Population covered by database at 1 January.

**Volume of second line antibiotics as a share of total volume**

**OECD indicator name**: Volume of cephalosporines and quinolones as a proportion of all systemic antibiotics prescribed.

**Coverage**: Population in the prescribing database with ≥1 prescription during the reference year.

**Numerator**: Sum DDDs of all ATC J01D and J01M prescriptions.

**Denominator**: Sum DDDs of all ATC J01 prescription in database.

**Polypharmacy among people aged 75 and over**

**OECD indicator name**: Proportion of 75 years and over who are taking more than 5 medications concurrently (>90 days excluding dermatological and antibiotics).

**Coverage**: Population aged 75 and over (at 1 January of the reference year) in the prescribing database with ≥1 prescription during the reference year.

**Numerator**: Number of individuals ≥75 years of age as of 1 January in database with ≥5 chronically used medications with different ATC codes at the fourth level (e.g. A10BA) during the reference year. This means that a different medication should only be counted if it is not within the same ATC codes at the fourth level. Medication here refers to subgroups of chemicals classified by the World Health Organization at the fourth level of the ATC classification system, 2017 version.

**Denominator**: Number of individuals ≥75 years of age at 1 January in database.

**Exclusions**:

* Dermatologicals for topical usage (Table 1).
* Antibiotics (J01).

**Table 1: Excluded ATC dermatologicals codes**

|  |  |
| --- | --- |
| **Code** | **Description** |
| S01A | Antibiotics for the eye |
| S02 | Otologicals |
| D01A | Antifungals for topical use |
| D02 | Emollients and protectives |
| D03 | Preparations for treatment of wounds and ulcers |
| D04 | Antipruritics, incl. antihistamines, anaesthetics, etc.  |
| D05A | Antipsoriatics for topical use |
| D06 | Antibiotics and chemotherapeutics for dermatological use |
| D07 | Corticosteroids, dermatological preparations |
| D08 | Antiseptics and disinfectants |
| D09A | Medicated dressings |
| D10A | Anti-acne preparations for topical use |

*(continued)*

**Table 1 (continued):** **Excluded ATC dermatologicals codes**

|  |  |
| --- | --- |
| **Code** | **Description** |
| D11AA | Antihidrotics |
| D11AC | Medicated shampoos |
| D11AE | Androgens for topical use |
| D11AF | Wart and anti-corn preparations |
| D11AH01 | Tacrolimus |
| D11AH02 | Pimecrolimus |
| D11AH03 | Cromoglicic acid |
| D11AH06 | Crisaborole |
| D11AX01-09 | Other dermatologicals |
| D11AX11-57 | Other dermatologicals |
| G01A | Antiinfectives and antiseptics, excl. combinations with corticosteroids |
| G01B | Combinations of corticosteroids and antiinfectives for gynaecological use |
| A01AB | Antiinfectives and antiseptics for local oral treatment |
| A01AC | Corticosteroids for local oral treatment |
| C05AA | Antihemorrhoidals with corticosteroids |

**Overall volume of opioids prescribed**

**OECD indicator name**: Overall volume of opioids prescribed (DDDs per 1000 population per day).

**Coverage**: Population aged 18 and over (on 1 January of the reference year) in prescribing database with ≥1 prescription during the reference year.

**Numerator**: Sum DDD of all ATC N02A prescriptions.

**Denominator**: Number of individuals ≥18 years of age on 1 January of the reference year in database

**Exclusions**:

* Opioids for the treatment of addiction (Table 2).

**Table 2: Excluded ATC opioids codes**

|  |  |
| --- | --- |
| **Code** | **Description** |
| N02AC52 | Methadone, combinations excl. psycholeptics |
| N02AE01 | Buprenorphine |

**Proportion of the population who are chronic opioid users**

**OECD indicator name**: Proportion of the population who are chronic opioid users (≥90 days’ supply in a year).

**Coverage**: Population aged 18 and over (on 1 January of the reference year) in prescribing database with ≥1 prescription during the reference year

**Numerator**: Number of individuals ≥18 years of age on 1 January of the reference year in database with 2 or more prescriptions of opioids (N02A) prescribed for ≥90 days in the year.

**Denominator**: Number of individuals ≥18 years of age on 1 January of the reference year in database.

**Exclusions**:

* Opioids for the treatment of addiction (Table 2).

**Proportion of older adults prescribed antipsychotics**

**OECD indicator name**: Proportion of people aged 65 and over prescribed antipsychotics.

**Coverage**: All persons aged 65 and over (on 1 January of reference year) in the prescribing database that show at least one prescription in the reference year.

**Numerator**: Number of individuals ≥65 years of age on 1 January of reference year with ≥1 prescription for any antipsychotic medication (ATC codes N05A) prescribed during the reference year.

**Denominator**: Number of individuals ≥65 years of age on 1 January of reference year in the national prescription database.